NCT03916640View on ClinicalTrials.gov

A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

March 1, 2019

Study Completion Date

March 1, 2019

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

ADO09 formulation

Subcutaneous injection of ADO09 formulation

DRUG

Placebo

Subcutaneous injection of 0.9% NaCl

DRUG

Symlin®

Subcutaneous injection of pramlintide

DRUG

Humulin®

Subcutaneous injection of human insulin

DRUG

Humalog®

Subcutaneous injection of insulin lispro

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Adocia
All Listed Sponsors
lead

Adocia

INDUSTRY

NCT03916640 - A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter